PDCD1 and non-small cell lung carcinoma: In addition, ipilimumab (CTLA-4 antibody) and nivolumab (PD-1 antibody) have therapeutic benefits for selected NSCLC (PD-L1 expression ≥ 1% and no EGFR/ALK aberrations).27